%PDF-1.4
%
101 0 obj
<>
endobj
98 0 obj
<>
endobj
168 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2003-07-08T19:00:35Z
2024-03-28T13:33:40-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-28T13:33:40-07:00
application/pdf
Heather
2002-306.aug
uuid:b854cc7c-1dd1-11b2-0a00-e60927fd5800
uuid:b854cc81-1dd1-11b2-0a00-6a0000000000
endstream
endobj
85 0 obj
<>
endobj
87 0 obj
<>
endobj
86 0 obj
<>
endobj
88 0 obj
<>
endobj
53 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 79 0 R/Type/Page>>
endobj
169 0 obj
[174 0 R]
endobj
170 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 72 714.5293 Tm
[(factor)19.7 (-alpha on fibroblast-like synoviocytes: paradoxical induction)]TJ
0 -1.25 TD
[(of IFN-gamma and )17.7 (TNF-alpha receptor expression. J Clin Immunol)]TJ
0 Tc 0 Tw T*
(1993;13:212-8.)Tj
-0.00011 Tc 0.02499 Tw -1.8 -1.25 Td
[(40.)-550.1 (T)69.9 (aylor DJ. Studies on the expression of the )17.7 (TNF alpha receptors)]TJ
1.8 -1.25 Td
(\(p55 and p75\) and their relative contributions to prostanoid )Tj
T*
(production and glycolytic rate by rheumatoid synovial fibroblasts in)Tj
T*
(vitro. Rheumatol Int 1993;13:89-93.)Tj
-1.8 -1.25 Td
[(41.)-550.1 (Brennan FM, Gibbons DL, Mitchell )17.7 (T)74 (,)-0.1 ( Cope )54.8 (AP)110.8 (, Maini RN,)]TJ
1.8 -1.25 Td
(Feldmann M. Enhanced expression of tumor necrosis factor receptor)Tj
T*
[(mRNA)-220.2 (and protein in mononuclear cells isolated from rheumatoid)]TJ
T*
(arthritis synovial joints. Eur J Immunol 1992;22:1907-12.)Tj
-1.8 -1.25 Td
[(42.)-550.1 (Dayer JM, Graham R, Russell G, Krane SM. Collagenase )]TJ
1.8 -1.25 Td
(production by rheumatoid synovial cells: stimulation by a human)Tj
T*
[(lymphocyte factor)54.8 (. Science 1977;195:181-3.)]TJ
-1.8 -1.25 Td
[(43.)-550.1 (Dayer JM, Beutler B, Cerami )54.8 (A. Cachectin/tumor necrosis factor)]TJ
1.8 -1.25 Td
(stimulates collagenase and prostaglandin E2 production by human)Tj
T*
(synovial cells and dermal fibroblasts. J Exp Med 1985;162:2163-8.)Tj
-1.8 -1.25 Td
[(44.)-550.1 (Rekdal O, Osterud B, Svendsen JS, )17.7 (W)39.8 (inber)17.7 (g JO. Evidence for)]TJ
1.8 -1.25 Td
(exclusive role of the p55 tumor necrosis factor \(TNF\) receptor in)Tj
T*
[(mediating the )17.7 (TNF-induced collagenase expression by human)]TJ
T*
(dermal fibroblasts. J Invest Dermatol 1996;107:565-8.)Tj
-1.8 -1.25 Td
[(45.)-550.1 (Jensen JM, Schutze S, Forl M, Kronke M, Proksch E. Roles for)]TJ
1.8 -1.25 Td
(tumor necrosis factor receptor p55 and sphingomyelinase in)Tj
T*
[(repairing the cutaneous permeability barrier)54.8 (. J Clin Invest)]TJ
0 Tc 0 Tw T*
(1999;104:1761-70.)Tj
-0.00011 Tc 0.02499 Tw -1.8 -1.25 Td
[(46.)-550.1 (Meller D, Li DQ, )17.7 (T)69.9 (seng SC. Regulation of collagenase, stromelysin,)]TJ
1.8 -1.25 Td
(and gelatinase B in human conjunctival and conjunctivochalasis)Tj
T*
[(fibroblasts by interleukin-1 beta and tumor necrosis factor)19.7 (-alpha.)]TJ
T*
[(Invest Ophthalmol )17.7 (V)59.8 (is Sci 2000;41:2922-9.)]TJ
-1.8 -1.25 Td
[(47.)-550.1 (Solomon )54.8 (A, Li DQ, Lee SB, )17.7 (T)69.9 (seng SC. Regulation of collagenase,)]TJ
1.8 -1.25 Td
(stromelysin, and urokinase-type plasminogen activator in primary)Tj
T*
(pterygium body fibroblasts by inflammatory cytokines. Invest)Tj
T*
[(Ophthalmol )17.7 (V)59.8 (is Sci 2000;41:2154-63.)]TJ
-1.8 -1.25 Td
[(48.)-550.1 (W)39.8 (u)-0.1 ( )36.8 (YM, Richards DW)91.7 (, Rowe DJ. Production of matrix-degrading)]TJ
1.8 -1.25 Td
[(enzymes and inhibition of osteoclast-like cell dif)17.7 (ferentiation by)]TJ
T*
(fibroblast-like cells from the periodontal ligament of human primary)Tj
T*
(teeth. J Dent Res 1999;78:681-9.)Tj
-1.8 -1.25 Td
[(49.)-550.1 (Singer CF)79.7 (, Marbaix E, Lemoine P)110.7 (, Courtoy PJ, Eeckhout )36.8 (Y)128.9 (. Local)]TJ
1.8 -1.25 Td
[(cytokines induce dif)17.7 (ferential expression of matrix )]TJ
T*
(metalloproteinases but not their tissue inhibitors in human )Tj
T*
(endometrial fibroblasts. Eur J Biochem 1999;259:40-5.)Tj
-1.8 -1.25 Td
[(50.)-550.1 (Y)99.8 (ao PM, Maitre B, Delacourt C, Buhler JM, Harf )54.8 (A, Lafuma C.)]TJ
1.8 -1.25 Td
[(Diver)17.7 (gent regulation of 92-kDa gelatinase and )17.7 (TIMP-1 by HBECs)]TJ
T*
[(in response to IL-1 beta and )17.7 (TNF-alpha. )54.8 (Am J Physiol)]TJ
0 Tc 0 Tw T*
(1997;273:L866-74.)Tj
-0.00011 Tc 0.02499 Tw -1.8 -1.25 Td
[(51.)-550.1 (Lotz M, Guerne P)91.7 (A. Interleukin-6 induces the synthesis of tissue)]TJ
1.8 -1.25 Td
(inhibitor of metalloproteinases-1/erythroid potentiating activity)Tj
T*
[(\(TIMP-1/EP)91.7 (A\). J Biol Chem 1991;266:2017-20.)]TJ
-1.8 -1.25 Td
[(52.)-550.1 (Silacci P)110.7 (, Dayer JM, Desgeor)17.7 (ges )54.8 (A, Peter R, Manueddu C, Guerne)]TJ
1.8 -1.25 Td
[(P)91.8 (A. Interleukin \(IL\)-6 and its soluble receptor induce )17.7 (TIMP-1)]TJ
T*
(expression in synoviocytes and chondrocytes, and block )Tj
T*
[(IL-1-induced collagenolytic activity)64.9 (. J Biol Chem )]TJ
0 Tc 0 Tw T*
(1998;273:13625-9.)Tj
-0.00011 Tc 0.02499 Tw -1.8 -1.25 Td
[(53.)-550.1 (Dembic Z, Loetscher H, Gubler U, et al. )17.7 (T)69.9 (wo human )17.7 (TNF receptors)]TJ
1.8 -1.25 Td
[(have similar extracellular)39.7 (, but distinct intracellular)39.7 (, domain)]TJ
T*
(sequences. Cytokine 1990;2:231-7.)Tj
-1.8 -1.25 Td
[(54.)-550.1 (Aupperle KR, Bennett BL, Boyle DL, )17.7 (T)69.9 (ak PP)110.7 (, Manning )54.8 (AM,)]TJ
1.8 -1.25 Td
(Firestein GS. NF-kappa B regulation by I kappa B kinase in primary)Tj
T*
(fibroblast-like synoviocytes. J Immunol 1999;163:427-33.)Tj
-1.8 -1.25 Td
[(55.)-550.1 (Aupperle K, Bennett B, Han Z, Boyle D, Manning )54.8 (A, Firestein G.)]TJ
1.8 -1.25 Td
(NF-kappa B regulation by I kappa B kinase-2 in rheumatoid arthritis)Tj
T*
[(synoviocytes. J Immunol 2001;166:2705-1)36.8 (1.)]TJ
-1.8 -1.25 Td
[(56.)-550.1 (Bondeson J, Brennan F)79.7 (, Foxwell B, Feldmann M. Ef)17.7 (fective )]TJ
1.8 -1.25 Td
(adenoviral transfer of I kappa B alpha into human fibroblasts and)Tj
T*
(chondrosarcoma cells reveals that the induction of matrix )Tj
33 80 Td
(metalloproteinases and proinflammatory cytokines is nuclear )Tj
T*
[(factor)19.7 (-kappa B dependent. J Rheumatol 2000;27:2078-89.)]TJ
-1.8 -1.25 Td
[(57.)-550.1 (Fassina G, Ferrari N, Brigati C, et al. )17.7 (T)35 (issue inhibitors of )]TJ
1.8 -1.25 Td
(metalloproteases: regulation and biological activities. Clin Exp)Tj
T*
[(Metastasis 2000;18:1)36.8 (1)36.8 (1-20.)]TJ
-1.8 -1.25 Td
[(58.)-550.1 (Mackay F)79.7 (, Rothe J, Bluethmann H, Loetscher H, Lesslauer )17.7 (W)91.8 (.)]TJ
1.8 -1.25 Td
[(Dif)17.7 (ferential responses of fibroblasts from wild-type and )]TJ
T*
[(TNF-R55-deficient mice to mouse and human )17.7 (TNF-alpha activation.)]TJ
T*
(J Immunol 1994;153:5274-84.)Tj
-1.8 -1.25 Td
[(59.)-550.1 (Chen )17.7 (V)128.9 (, Croft D, Purkis P)110.7 (, Kramer IM. Co-culture of synovial)]TJ
1.8 -1.25 Td
[(fibroblasts and dif)17.7 (ferentiated U937 cells is suf)17.7 (ficient for high )]TJ
T*
(interleukin-6 but not interleukin-1 beta or tumour necrosis)Tj
T*
[(factor)19.7 (-alpha release. Br J Rheumatol 1998;37:148-56.)]TJ
-1.8 -1.25 Td
[(60.)-550.1 (Charles P)110.8 (, Elliott MJ, Davis D, et al. Regulation of cytokines,)]TJ
1.8 -1.25 Td
(cytokine inhibitors, and acute-phase proteins following )Tj
T*
(anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol)Tj
0 Tc 0 Tw T*
(1999;163:1521-8.)Tj
-0.00011 Tc 0.02499 Tw -1.8 -1.25 Td
[(61.)-550.1 (W)79.9 (ood JM, Katschke KJ Jr)39.7 (, )17.7 (T)69.9 (okuhira M, et al. Reduction of )]TJ
1.8 -1.25 Td
(inflammatory cytokines and prostaglandin E)Tj
0 Tc 0 Tw 5.2 0 0 5.2 478.9778 531.8893 Tm
(2)Tj
-0.00011 Tc 0.02499 Tw 8 0 0 8 483.7778 534.5293 Tm
(by IL-13 gene therapy)Tj
-18.4722 -1.25 Td
(in rheumatoid arthritis synovium. J Immunol 2000;165:2755-63.)Tj
-1.8 -1.25 Td
[(62.)-550.1 (Alaaeddine N, DiBattista JA, Pelletier JP)110.8 (, et al. Osteoarthritic)]TJ
1.8 -1.25 Td
(synovial fibroblasts possess an increased level of tumor necrosis)Tj
T*
[(factor)19.7 (-receptor 55 \(TNF-R55\) that mediates biological activation by)]TJ
T*
(TNF-alpha. J Rheumatol 1997;24:1985-94.)Tj
-1.8 -1.25 Td
[(63.)-550.1 (Crof)17.7 (ford LJ. COX-2 in synovial tissues. Osteoarthritis Cartilage)]TJ
0 Tc 0 Tw 1.8 -1.25 Td
(1999;7:406-8.)Tj
-0.00011 Tc 0.02499 Tw -1.8 -1.25 Td
[(64.)-550.1 (Gerritsen ME, Shen CP)110.7 (, Perry CA. Synovial fibroblasts and the)]TJ
1.8 -1.25 Td
(sphingomyelinase pathway: sphingomyelin turnover and ceramide)Tj
T*
(generation are not signaling mechanisms for the actions of tumor)Tj
T*
[(necrosis factor)19.7 (-alpha. )54.8 (Am J Pathol 1998;152:505-12.)]TJ
-1.8 -1.25 Td
[(65.)-550.1 (Kuwano K, Hara N. Signal transduction pathways of apoptosis and)]TJ
1.8 -1.25 Td
[(inflammation induced by the tumor necrosis factor receptor family)64.8 (.)]TJ
T*
(Am J Respir Cell Mol Biol 2000;22:147-9.)Tj
-1.8 -1.25 Td
[(66.)-550.1 (Herbein G, O\325Brien )17.7 (W)110.9 (A. )17.7 (T)35 (umor necrosis factor \(TNF\)-alpha and)]TJ
1.8 -1.25 Td
(TNF receptors in viral pathogenesis. Proc Soc Exp Biol Med)Tj
0 Tc 0 Tw T*
(2000;223:241-57.)Tj
-0.00011 Tc 0.02499 Tw -1.8 -1.25 Td
[(67.)-550.1 (Rath PC, )54.8 (Aggarwal BB. )17.7 (TNF-induced signaling in apoptosis. J Clin)]TJ
1.8 -1.25 Td
(Immunol 1999;19:350-64.)Tj
-1.8 -1.25 Td
[(68.)-550.1 (Zhang HG, Huang N, Liu D, et al. Gene therapy that inhibits)]TJ
1.8 -1.25 Td
(nuclear translocation of nuclear factor kappa B results in tumor)Tj
T*
(necrosis factor alpha-induced apoptosis of human synovial )Tj
T*
[(fibroblasts. )54.8 (Arthritis Rheum 2000;43:1094-105.)]TJ
-1.8 -1.25 Td
[(69.)-550.1 (May MJ, Ghosh S. IkappaB kinases: kinsmen with dif)17.7 (ferent crafts.)]TJ
1.8 -1.25 Td
(Science 1999;284:271-3.)Tj
-1.8 -1.25 Td
[(70.)-550.1 (Gerspach J, Gotz )54.8 (A, Zimmermann G, Kolle C, Bottinger H, Grell)]TJ
1.8 -1.25 Td
(M. Detection of membrane-bound tumor necrosis factor \(TNF\): an)Tj
T*
[(analysis of )17.7 (TNF-specific reagents. Microsc Res )17.7 (T)69.9 (ech )]TJ
0 Tc 0 Tw T*
(2000;50:243-50.)Tj
-0.00011 Tc 0.02499 Tw -1.8 -1.25 Td
[(71.)-550.1 (Chan FK, Chun HJ, Zheng L, Siegel RM, Bui KL, Lenardo MJ. )54.8 (A)]TJ
1.8 -1.25 Td
[(domain in )17.7 (TNF receptors that mediates ligand-independent receptor)]TJ
T*
(assembly and signaling. Science 2000;288:2351-4.)Tj
-1.8 -1.25 Td
[(72.)-550.1 (Inoue J, Ishida )17.7 (T)74 (,)-0.1 ( )17.7 (T)69.9 (sukamoto N, et al. )17.7 (T)35 (umor necrosis factor)]TJ
1.8 -1.25 Td
[(receptor)19.7 (-associated factor \(TRAF\) family: adapter proteins that)]TJ
T*
(mediate cytokine signaling. Exp Cell Res 2000;254:14-24.)Tj
-1.8 -1.25 Td
[(73.)-550.1 (Kassiotis G, Kollias G. Uncoupling the proinflammatory from the)]TJ
1.8 -1.25 Td
(immunosuppressive properties of tumor necrosis factor \(TNF\) at the)Tj
T*
[(p55 )17.7 (TNF receptor level: implications for pathogenesis and therapy)]TJ
T*
(of autoimmune demyelination. J Exp Med 2001;193:427-34.)Tj
-1.8 -1.25 Td
[(74.)-550.1 (Kassiotis G, Kollias G. )17.7 (TNF and receptors in or)17.7 (gan-specific )]TJ
1.8 -1.25 Td
(autoimmune disease: multi-layered functioning mirrored in animal)Tj
T*
(models. J Clin Invest 2001;107:1507-8.)Tj
ET
0 0 0 1 K
54 54 m
558 54 l
S
BT
/T1_1 1 Tf
8 0 0 8 424.3613 35.9844 Tm
(The Journal of Rheumatology 2003; 30:8)Tj
0 Tc 0 Tw -46.2952 -0.0313 Td
(1690)Tj
ET
0 0 0 0 k
/GS0 gs
109.25 59.1 396.47 -10.84 re
f*
0.5 w
109.25 59.1 396.47 -10.84 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_2 8 Tf
117.48 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2003. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_3 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
79 0 obj
<>stream
8;Z\6$ZbPe#itt$e90Wtep`^BjgK.iD^I;XC53p6QGotSlsp'`7@^P740FY%j/.+o
:QCe>k#d2DTZ_Uhs*m&"VZj/^6cUql(-,*k7E)kQNModJHG?J8#5"s!..#ej]
CdJ)?#)r.C[2O;aY\amAi`[^5-()e3l)0e0GN(),*7cc0DiMouY`ff%&L*OC1a>9g
pRCa!?N)f=a:.*2M^qZN!\ggcB!>S251kDbpb=mZ&O0JinfIBu.u%F&dkJ*k
9#==Pk.etf
ZPnoNe^9%e\OLjW2oYb1a^gi-j`i6#;RWOir=dF1;B;)DhcZ&+3_;8!CT0k+Y].+RRi8]Xk6Y(&o-[YkdFLYZFl+4et<,\@dWd
Q%dsia*XA6SD%0BM*[kWLBf,'5KjHOTqO[[QmU(0XnKZEbaKNqm>l=?`V8aG5rK<^
endstream
endobj
83 0 obj
[/Indexed/DeviceRGB 255 82 0 R]
endobj
82 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
121 0 obj
<>
endobj
105 0 obj
<>
endobj
145 0 obj
<>
endobj
173 0 obj
<>
endobj
104 0 obj
<>
endobj
139 0 obj
<>stream
HiPSYBPl$OڭGED]FmDDdkY%$Q,*8K]2Z==T=KL[u9O]37p jM(_%Mǿɸ`+,5cflT+ⲕ9õr@ې֊heÄMҧ==7xxzz
S"~b^1aO־>-O0G%<ޕ/
E^M$'zŴ'2L7b:bxXQZ
OJqzycia8Y-6ggF`$U`#5~o13N8ĘyiCab[lvfY.]Y@Xpͪ͢E8vΏXκ͆`m]=>1u;D9<]lY;V9aN!NO;]"]:#FxmbQ";ڳZsUzteU"/'mA}lظ6-B+(U2}XBIh%Dr]go|Qw `Gl-s/oȖ:WZΗI
inANvFR-d9*vQN\Cp 5@CG}Pn0tCN(LOqFg=NѕLު*9+Nu274W'/=ah/Ljȯy'&-hpL\οIV|Y6Lk;q=U܄
RҦQ%r=$$riE\tY\NwL>C0NXAbg7|Z&\O{Ȋ8rA2U
uC6[CNC!-:(Ƃ1=0@52[\2]A+Òe EYrEO16 m!?'>25+?Iױ/iɋ$GzwªM/Zjֽ#u<_L*SQUo1[8ܘ"6j;IxBgbDc%'_'H@R(wɑ37&qC0qF
U>B9shZ+OUE6u
E(::KvBZZ2YB=z$M!f P{+tEo~+ᾙPd<5Ч.'V Ya{lGR
3T0Kl/agݝ͛{;p1-Wub<9b.$j[wox
<&7v=$Hn=8O'ݥ[5ζUy8!L˶U?0?4Ͷ{3Jch%KuLLV:+'9KRD)m}"|,Уo[
{]#-&4H5Y@JQ,UұkN 5hchЫ\ׅ#F!Ls(FF-VK~@=Ε}?~V#pldm:
K7?vPg`}7~98g +6Vf6W"X~Փh#2s5{[/"\ݡ0a
5XvJޕ>VPJȄŐy#762+ٌ6!{bMw5{ _获{$ѹ_D#rTDSKLl)h-
Q !QMu6-N NUb%dզ"mxM8h)w<([0%>%Vm\aN-/.9,xJ.31
7c(HɠIiu/8Z)YAL鄙Mh7Z|/HY5b[%D:$G:{ɶױbo^:A }ˍZnEнS{i':Бp<>x9 ڬ+PH@;
fلiNzRbNm|'Ԍ:riT?2~K`s7+ij+KSh5\FϚ/y}1JK^H}h{*f
M
X2%
䫳ϱ
8q㪝9/(_%s6
RTʘB1
Nl?pvE!~mqZ,8>*&$sOs4<=@E>ehRćtғCP^m
[g(G}MNC%z˪:9[6NubcV+x~%U8LAv`^J"t;(G3Wh<6Б83~_A:ۤ1ݟ땱cr !+ֱ84
y#pvMj>
XYxFwOW?|oUtRVMႿc`(agxn`?'\&tCke
ȥ~
p"=ר̆v]ǧ_0cvbpCђzc{_\lAnEoƒ4z&ުra;xw
{E-5f{=h(-s冻j+0j%6R?]5
"|
hZGn2͐n_H }jvl{#c
~9 f7b9^x~s?!< \Ҝavp[CƎrGUm